Laronidase for treating mucopolysaccharidosis type I

Area of Science:

• Biochemistry
• Genetics
• Pediatrics

Background:

• Mucopolysaccharidoses are inherited metabolic disorders resulting from deficient lysosomal enzymes.
• Glycosaminoglycan (GAG) accumulation causes progressive cellular damage affecting multiple organ systems.
• Enzyme replacement therapy (ERT) is an emerging treatment for specific mucopolysaccharidosis subtypes.

Purpose of the Study:

• To evaluate the efficacy and safety of laronidase as an ERT for mucopolysaccharidosis type I (MPS I).

Main Methods:

• A systematic literature review was performed, searching CENTRAL, Pubmed, EMBASE, and LILACS databases for randomized controlled trials.
• The search was last updated in June 2006.
• Due to the inclusion of only one study, a meta-analysis was not possible.

Main Results:

• The pivotal placebo-controlled trial showed a significant reduction in urinary GAG excretion in laronidase-treated MPS I patients over 26 weeks.
• Improvements in vital capacity and performance on specific physical tasks were observed.
• No serious adverse events or deaths were attributed to laronidase treatment.

Conclusions:

• Laronidase appears to be a safe and effective therapeutic agent for MPS I.
• The observed reduction in GAGs and improvements in physical function support laronidase's potential in managing MPS I.